Esomeprazole Magnesium Capsule, Delayed Release
Product Images NDC 80425-0331

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 80425-0331). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description (Description)

Chemical structure of esomeprazole magnesium showing molecular arrangement including methoxy groups, nitrogen and sulfur atoms, and magnesium ion complex with three water molecules.*

FDA Label Image

Label 1 (Esomeprazole Magnesium Dr 40mg 80425 0331 01)

Label for Esomeprazole Magnesium DR 40 mg capsule from Advanced Rx Pharmacy of Tennessee, LLC, Nashville, TN. The label includes a compare to NEXIUM note, NDC numbers, source NDC, lot number, expiration date 2/29/2024, and a barcode. The storage temperature is specified as 20°-25°C (68°-77°F).*

FDA Label Image

Label 2 (Esomeprazole Magnesium Dr 40mg 80425 0331 02)

Esomeprazole Magnesium DR 40 mg capsule label from Advanced Rx Pharmacy of Tennessee, LLC, Nashville, TN. The label includes storage instructions, comparison to Nexium, NDC 80425-0331-02, lot number, expiration date 2/29/2024, and a barcode. The label indicates it is a human prescription drug in delayed-release oral capsule form.*

FDA Label Image

Label 3 (Esomeprazole Magnesium Dr 40mg 80425 0331 03)

Esomeprazole Magnesium DR 40 mg delayed-release capsule label produced by Advanced Rx Pharmacy of Tennessee, LLC. The label includes storage instructions, comparison to NEXIUM, NDC numbers, lot number, expiration date, and originates from Camber Pharmacy with relevant lot and expiration details.*

FDA Label Image

Fig 2 (Fig 2)

A line graph showing the percent maintained over six months for Esomeprazole Magnesium Delayed-Release Capsules at 40 mg, 20 mg, 10 mg doses, and a placebo group. The 40 mg dosage group maintains near 100% throughout, with 20 mg and 10 mg groups showing decreasing trends, and the placebo group declining more steeply.*

FDA Label Image

Fig 3 (Fig 3)

A line graph depicting the percent maintained over a 6-month period for Esomeprazole Magnesium delayed-release capsules at 40 mg, 20 mg, and 10 mg doses, compared with placebo. The vertical axis shows percent maintained, and the horizontal axis shows time in months, with legends indicating sample sizes for each group.*

FDA Label Image

Fig 4 (Fig 4)

A line graph showing the percentage of patients symptom-free over a 28-day diary period. It compares three groups: Esomeprazole Magnesium Delayed-Release Capsules 40 mg, 20 mg, and placebo, indicating different efficacy trends across the study duration.*

FDA Label Image

Fig 5 (Fig 5)

A line graph comparing the percentage of patients symptom-free over 28 days among three groups: Esomeprazole Magnesium Delayed-Release Capsules 40 mg, 20 mg, and placebo. The y-axis shows percent symptom-free, and the x-axis shows diary days from 0 to 28. The 40 mg and 20 mg groups show higher symptom-free percentages than placebo throughout the study period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.